El interés en corto de Vanda Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Vanda Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

Vanda Pharmaceuticals (NASDAQ:VNDA) Bolsa, Informe de interés en corto

VANDA PHARMACEUTICALS INC

Vanda Pharma

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals Inc

<p>Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:&nbsp;VNDA) today announced the first dose in the&nbsp;first-in-human&nbsp;clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide (ASO) therapeutic, for a patient with a rare variant in the&nbsp;<i>IGHMBP2&nbsp;</i>gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S).</p>
<p>VCA-894A is being developed for a patient who was first diagnosed at the age of 5 with a rare subtype of CMT disease known as CMT2S.1 CMT2S is an inherited neuromuscular disorder that progressively leads to muscle weakness and loss of motor function, and has an estimated prevalence of less than 1 in 1,000,000 worldwide.2 The severity and clinical presentations of CMT2S are influenced by the diverse genetic variants associated with CMT disease.</p>
<p>VCA-894A targets a patient-specific IGHMBP2 variant and has been previously shown to restore expression levels of the IGHMBP2 gene in an "organ-on-a-chip" NMJ (neuromuscular junction) system derived from the patient's cells, highlighting the exciting potential of this approach for personalized therapeutics for rare diseases. This platform has the potential to unlock the development of treatments that can address significantly unmet medical needs based on identified causative genetic variants.</p>


News

VNDA

Vanda Pharma Announces First Dose In First-In-Human Clinical Trial To Evaluate Safety And Tolerability Of VCA-894A, ASO Therapeutic, For Patient With Rare Variant In IGHMBP2 Gene Causing Charcot-Marie-Tooth Disease Type 2S

<p>Cantor Fitzgerald  analyst Olivia Brayer   assumes Vanda Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Overweight rating and announces Price Target of $13.</p>


Price Target

Initiation

Analyst Ratings

Cantor Fitzgerald Assumes Vanda Pharmaceuticals at Overweight, Announces Price Target of $13

<p>Vanda Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) affirms FY2025 sales outlook from $210.00 million-$250.00 million to $210.00 million-$250.00 million vs $222.86 million estimate.</p>


Guidance

Vanda Pharmaceuticals Affirms FY2025 Sales Guidance of $210.00M-$250.00M vs $222.86M Est

<p>Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.60) by 16.67 percent. This is a 614.29 percent decrease over losses of $(0.07) per share from the same period last year.  The company reported quarterly sales of $50.04 million which beat the analyst consensus estimate of $45.13 million by 10.87 percent.  This is a 5.43 percent increase over sales of $47.46 million the same period last year.</p>


Earnings

Earnings Beats

Vanda Pharma Q1 GAAP EPS $(0.50) Beats $(0.60) Estimate, Sales $50.04M Beat $45.13M Estimate

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates Vanda Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Buy and maintains $20 price target.</p>


Reiteration

HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

<p>Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Vanda Pharma to report an <strong>earnings per share</strong> (EPS) of $-0.02.</p>
<p>Vanda Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.06, which was followed by a 5.96% drop in the share price the next day.</p>
<p>Here's a look at Vanda Pharma's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.14</td>
<td>-0.16</td>
<td>-0.21</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.08</td>
<td>-0.09</td>
<td>-0.08</td>
<td>-0.07</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746558207_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Vanda Pharma were trading at $4.59 as of May 05. Over the last 52-week period, shares are down 18.75%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analyst Observations about Vanda Pharma</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Vanda Pharma.</p>
<p>The consensus rating for Vanda Pharma is Buy, based on 2 analyst ratings. With an average one-year price target of $20.0, there's a potential 335.73% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Emergent BioSolutions, 2seventy bio and Lexicon Pharmaceuticals, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Emergent BioSolutions, with an average 1-year price target of $15.0, suggesting a potential 226.8% upside.</li>
<li>Analysts currently favor an Neutral trajectory for 2seventy bio, with an average 1-year price target of $5.0, suggesting a potential 8.93% upside.</li>
<li>Analysts currently favor an Buy trajectory for Lexicon Pharmaceuticals, with an average 1-year price target of $3.8, suggesting a potential 17.21% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Emergent BioSolutions, 2seventy bio and Lexicon Pharmaceuticals are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vanda Pharmaceuticals</td>
<td>Buy</td>
<td>17.48%</td>
<td>$50.59M</td>
<td>-0.91%</td>
</tr>
<tr>
<td>Emergent BioSolutions</td>
<td>Buy</td>
<td>-29.86%</td>
<td>$71.30M</td>
<td>-6.32%</td>
</tr>
<tr>
<td>2seventy bio</td>
<td>Neutral</td>
<td>-72.61%</td>
<td>$-5.92M</td>
<td>-8.89%</td>
</tr>
<tr>
<td>Lexicon Pharmaceuticals</td>
<td>Buy</td>
<td>3682.62%</td>
<td>$26.21M</td>
<td>-20.81%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Vanda Pharma ranks highest in Revenue Growth among its peers. It also has the highest Gross Profit margin. However, it has the lowest Return on Equity.</p>
<h3>Unveiling the Story Behind Vanda Pharma</h3>
<p>Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) &amp; nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.</p>
<h3>Key Indicators: Vanda Pharma's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Vanda Pharma's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>17.48%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Vanda Pharma's net margin is impressive, surpassing industry averages. With a net margin of <strong>-9.24%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Vanda Pharma's ROE excels beyond industry benchmarks, reaching <strong>-0.91%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-0.75%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Vanda Pharma's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.02</strong>.</p>
<p><a href="https://www.benzinga.com/quote/VNDA/earnings"><strong>To track all earnings releases for Vanda Pharma visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Glimpse of Vanda Pharma's Earnings Potential

<p>Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application (NDA) for Bysanti&#x2122; (milsaperidone) has been filed, and that at this time no potential review issues have been identified. The FDA has set February 21, 2026 as the target date for decision on this application.</p>


Vanda Pharma Announces FDA Filing of Bysanti NDA, Decision Slated For February 2026

<h3>Gainers</h3>
<ul>
<li><strong>Community Health Sys</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares rose 13.2% to $2.75 during Wednesday's after-market session. The company's market cap stands at $382.0 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>Candel Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock increased by 11.55% to $5.31. The company's market cap stands at $250.8 million. </li>
<li><strong>Ovid Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) stock increased by 8.61% to $0.35. The company's market cap stands at $25.0 million. </li>
<li><strong>Adaptimmune Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 7.6% to $0.28. The company's market cap stands at $73.8 million. </li>
<li><strong>Vanda Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) stock increased by 7.18% to $4.64. The market value of their outstanding shares is at $270.6 million. </li>
<li><strong>Clearside Biomedical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) shares rose 6.83% to $0.85. The company's market cap stands at $65.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Relmada Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) shares declined by 20.4% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $17.8 million. </li>
<li><strong>Ensysce Biosciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 19.62% to $2.95. The company's market cap stands at $4.1 million. </li>
<li><strong>Citius Oncology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock fell 9.33% to $0.61. The market value of their outstanding shares is at $43.4 million. </li>
<li><strong>Zhengye Biotechnology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares fell 8.03% to $7.34. The company's market cap stands at $347.8 million. </li>
<li><strong>60 Degrees</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares fell 6.98% to $2.8. The market value of their outstanding shares is at $4.1 million. </li>
<li><strong>INVO Fertility</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) stock decreased by 6.12% to $1.8. The company's market cap stands at $8.8 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

ADAP

CADL

CLSD

CTOR

ENSC

NAYA

OVID

RLMD

SXTP

ZYBT

12 Health Care Stocks Moving In Wednesday's After-Market Session

<p>WASHINGTON, April 23, 2025 /PRNewswire/ --&nbsp;Vanda Pharmaceuticals Inc. ("Vanda") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) today announced that FDA bureaucrats have committed to delay Vanda's request for a hearing on the approvability of tradipitant for gastroparesis. Rather than take accountability, FDA bureaucrats identify a new scapegoat: newly appointed Commissioner, Dr. Martin Makary, and reductions in force.</p>
<p>FDA last night represented to a federal court that the April 1 reduction in force is partially to blame for the Center for Drug and Evaluation and Research's delay of at least 6 more months to provide its recommendation on whether&nbsp;the Commissioner should hold a hearing. But this cannot be true. Commissioner Makary said that any cuts were not to scientists or reviewers, the very individuals who supposedly need more time. This excuse is also suspect because CDER, in prior matters, has requested the same or longer delay to provide hearing recommendations: CDER took six months to submit a proposed order on the Hetlioz jet lag hearing request and likewise requested six months for the Hetlioz insomnia application.</p>
<p>It is unfair for CDER and its lawyers to blame the recent reductions in force for their habitual institutional delays on hearing requests. These statements also conceal the extraordinary fact that FDA has denied every hearing request on new drug approvability for at least the past decade.</p>
<p>FDA bureaucrats have created policies to avoid scrutiny of their decision-making by habitually denying hearings. FDA's office of chief counsel and DOJ have repeatedly defended FDA's right to act unlawfully when confronted by federal judges. When considering FDA's delay in resolving Vanda's hearing request in a prior instance, a federal judge pointedly asked FDA whether it was "conceding that the [HHS] Secretary is presently not complying with the statute," and a DOJ lawyer replied, "Yes, your Honor".</p>
<p>We urge Commissioner Makary to step in and restore adherence to the law at FDA; targeted RIFs are not to blame for FDA's culture of delay and closemindedness. Commissioner Makary and Secretary Kennedy have been clear that "radical transparency and common sense" should be the operating culture of the Agency. We also urge Attorney General Bondi to stop DOJ lawyers from defending unlawful Agency actions.</p>
<p>"Vanda has fought for 'transparency and common sense' for years because rational innovation can only thrive in a democracy and not in a bureaucracy. It is time for FDA and DOJ to stop fighting innovators like Vanda, focus on what is broken and listen to ideas of how it can be fixed, and usher in a new era of rational and transparent decision making," said Dr. Mihael Polymeropoulos, Vanda's President, CEO and Chairman of the Board.</p>


Vanda Pharma Says FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and Reductions In Force At FDA

<p>Analysts' ratings for Vanda Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Vanda Pharmaceuticals, revealing an average target of $18.8, a high estimate of $20.00, and a low estimate of $18.00. This current average reflects an increase of 2.17% from the previous average price target of $18.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743516079_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Vanda Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vanda Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vanda Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Vanda Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VNDA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Vanda Pharmaceuticals analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Vanda Pharmaceuticals</h2>
<p>Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) &amp; nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.</p>
<h3>Vanda Pharmaceuticals: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Vanda Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>17.48%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Vanda Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-9.24%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Vanda Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.91%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-0.75%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.02</strong>, Vanda Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals

Biotech

General

Vanda Pharmaceuticals Submits An NDA To The FDA For Bysanti For The Treatments Of Acute Bipolar I Disorder And Schizophrenia

<p>Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, for a patient with a rare variant in the <i>IGHMBP2 </i>gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S).</p>


Vanda Pharmaceuticals Unveils Potential ASO Treatment for Rare Nerve Disease Charcot-Marie-Tooth Type 2S

<p>Ratings for Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Vanda Pharma, presenting an average target of $18.4, a high estimate of $20.00, and a low estimate of $18.00. This upward trend is evident, with the current average reflecting a 2.22% increase from the previous average price target of $18.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739880054_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Vanda Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vanda Pharma. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Vanda Pharma compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Vanda Pharma's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Vanda Pharma's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VNDA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Vanda Pharma analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Vanda Pharma: A Closer Look</h2>
<p>Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) &amp; nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.</p>
<h3>Vanda Pharma's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Vanda Pharma's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>22.76%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-11.17%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Vanda Pharma's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.98%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Vanda Pharma's ROA excels beyond industry benchmarks, reaching <strong>-0.82%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Vanda Pharma's debt-to-equity ratio is below the industry average at <strong>0.01</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Vanda Pharma In The Eyes Of 5 Experts

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   maintains Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Buy and raises the price target from $18 to $20.</p>


HC Wainwright & Co. Maintains Buy on Vanda Pharma, Raises Price Target to $20

<p>Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) sees FY2025 sales of $210.000 million-$250.000 million vs $284.90 million analyst estimate.</p>


Vanda Pharma Sees FY2025 Sales $210.000M-$250.000M vs $284.90M Est

<p>Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 100 percent decrease over losses of $(0.04) per share from the same period last year.  The company reported quarterly sales of $53.19 million which beat the analyst consensus estimate of $52.25 million by 1.79 percent.  This is a 17.48 percent increase over sales of $45.27 million the same period last year.</p>


Vanda Pharma Q4 EPS $(0.08) Beats $(0.11) Estimate, Sales $53.19M Beat $52.25M Estimate

ABNB

AENT

AGIO

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BTOC

CBRE

CLBT

CNVS

COHU

COIN

CROX

CYBR

DDOG

DKNG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Buy and maintains $18 price target.</p>


HC Wainwright & Co. Reiterates Buy on Vanda Pharma, Maintains $18 Price Target

Press Releases

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Comments

Vanda Pharmaceuticals

Interés en corto

Vanda Pharmaceuticals (NASDAQ:VNDA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL